

Cullen M Taniguchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6248800/publications.pdf>

Version: 2024-02-01

137
papers

6,999
citations

159585

30
h-index

60623

81
g-index

151
all docs

151
docs citations

151
times ranked

11384
citing authors

#	ARTICLE	IF	CITATIONS
1	Critical nodes in signalling pathways: insights into insulin action. <i>Nature Reviews Molecular Cell Biology</i> , 2006, 7, 85-96.	37.0	2,299
2	New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. <i>Nature</i> , 2008, 454, 1000-1004.	27.8	964
3	Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 108-118.e4.	1.3	270
4	Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. <i>Clinical Cancer Research</i> , 2019, 25, 2194-2205.	7.0	268
5	Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKC δ . <i>Cell Metabolism</i> , 2006, 3, 343-353.	16.2	249
6	Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. <i>Journal of Clinical Investigation</i> , 2005, 115, 718-727.	8.2	237
7	Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and neclin. <i>Nature Cell Biology</i> , 2005, 7, 601-611.	10.3	202
8	Phosphoinositide 3-kinase regulatory subunit p85 β suppresses insulin action via positive regulation of PTEN. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12093-12097.	7.1	149
9	The Phosphoinositide 3-Kinase Regulatory Subunit p85 β Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling. <i>Cancer Research</i> , 2010, 70, 5305-5315.	0.9	140
10	Suppression of PGC-1 β Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma. <i>Cell Reports</i> , 2015, 12, 116-127.	6.4	140
11	Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. <i>Nature Medicine</i> , 2013, 19, 1325-1330.	30.7	125
12	PHD Inhibition Mitigates and Protects Against Radiation-Induced Gastrointestinal Toxicity via HIF2. <i>Science Translational Medicine</i> , 2014, 6, 236ra64.	12.4	120
13	Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	102
14	Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?. <i>Science China Life Sciences</i> , 2017, 60, 1114-1124.	4.9	96
15	Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. <i>FASEB Journal</i> , 2012, 26, 2187-2196.	0.5	93
16	A liver Hif-2 β -Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. <i>Nature Medicine</i> , 2013, 19, 1331-1337.	30.7	90
17	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894.	7.0	76
18	The p85 β Regulatory Subunit of Phosphoinositide 3-Kinase Potentiates c-Jun N-Terminal Kinase-Mediated Insulin Resistance. <i>Molecular and Cellular Biology</i> , 2007, 27, 2830-2840.	2.3	74

#	ARTICLE	IF	CITATIONS
19	Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. <i>Gastroenterology</i> , 2022, 162, 2018-2031.	1.3	62
20	Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. <i>Clinical Cancer Research</i> , 2021, 27, 5912-5921.	7.0	57
21	Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NF κ B) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance. <i>Diabetologia</i> , 2009, 52, 1197-1207.	6.3	54
22	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , 2022, 7, .	11.9	52
23	Dosimetric Analysis of Organs at Risk During Expiratory Gating in Stereotactic Body Radiation Therapy for Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1090-1095.	0.8	50
24	Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. <i>Practical Radiation Oncology</i> , 2020, 10, e495-e507.	2.1	50
25	Microbiome factors in HPV-driven carcinogenesis and cancers. <i>PLoS Pathogens</i> , 2020, 16, e1008524.	4.7	48
26	Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 133, 54-61.	0.6	37
27	A Two-Step Procedure for the Conversion of α,β -Unsaturated Aldehydes into α -Azido- β,β -Unsaturated Nitriles. <i>Journal of Organic Chemistry</i> , 2001, 66, 7191-7194.	3.2	35
28	Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. <i>Cancer</i> , 2018, 124, 1701-1709.	4.1	35
29	APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. <i>Nature Cancer</i> , 2021, 2, 1338-1356.	13.2	35
30	Fasting Reduces Intestinal Radiotoxicity, Enabling Dose-Escalated Radiation Therapy for Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 537-547.	0.8	33
31	EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 659-670.e18.	1.0	33
32	Dose escalation for locally advanced pancreatic cancer: How high can we go?. <i>Advances in Radiation Oncology</i> , 2018, 3, 693-700.	1.2	30
33	Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. <i>Advances in Radiation Oncology</i> , 2017, 2, 403-415.	1.2	29
34	Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. <i>Cancer Research</i> , 2019, 79, 2327-2338.	0.9	27
35	Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. <i>Scientific Reports</i> , 2016, 6, 38273.	3.3	24
36	Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892.	2.8	23

#	ARTICLE	IF	CITATIONS
37	Synthesis of E-vinylogous (R)-amino acid derivatives via metal-catalyzed allylic substitutions on enzyme-derived substrates. <i>Tetrahedron: Asymmetry</i> , 2005, 16, 1655-1661.	1.8	22
38	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.	3.7	21
39	Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. <i>VideoGIE</i> , 2019, 4, 223-225.	0.7	20
40	Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 990-997.	1.4	19
41	Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic. <i>JAMA Network Open</i> , 2020, 3, e2015100.	5.9	19
42	Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. <i>Advances in Radiation Oncology</i> , 2021, 6, 100763.	1.2	19
43	NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 66-69.	1.7	19
44	Performance Status Restriction in Phase III Cancer Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1322-1326.	4.9	18
45	Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. <i>Clinical and Translational Radiation Oncology</i> , 2019, 19, 59-65.	1.7	17
46	Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. <i>Current Problems in Cancer</i> , 2020, 44, 100607.	2.0	17
47	Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1399-1400.	0.8	16
48	Cancer Research after COVID-19: Where Do We Go from Here?. <i>Cancer Cell</i> , 2020, 37, 637-638.	16.8	16
49	Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image Guided Stereotactic Body Radiation Therapy in the Abdomen. <i>Practical Radiation Oncology</i> , 2020, 10, 434-442.	2.1	16
50	Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1901.	3.7	15
51	Stem cell enriched-epithelial spheroid cultures for rapidly assaying small intestinal radioprotectors and radiosensitizers in vitro. <i>Scientific Reports</i> , 2018, 8, 15410.	3.3	13
52	Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation. <i>Scientific Reports</i> , 2019, 9, 1949.	3.3	13
53	Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 274-285.	2.2	13
54	Anal Adenocarcinoma: A Rare Malignancy in Need of Multidisciplinary Management. <i>JCO Oncology Practice</i> , 2020, 16, 635-640.	2.9	12

#	ARTICLE	IF	CITATIONS
55	Dosimetric Uncertainties Resulting From Interfractional Anatomic Variations for Patients Receiving Pancreas Stereotactic Body Radiation Therapy and Cone Beam Computed Tomography Image Guidance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1298-1309.	0.8	12
56	Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. <i>Clinical and Translational Radiation Oncology</i> , 2017, 4, 39-45.	1.7	11
57	EUS-guided placement of fiducial markers for the treatment of pancreatic cancer. <i>VideoGIE</i> , 2019, 4, 403-406.	0.7	11
58	The radiotherapy quality assurance gap among phase III cancer clinical trials. <i>Radiotherapy and Oncology</i> , 2022, 166, 51-57.	0.6	11
59	Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100621.	1.2	10
60	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. <i>Cancer Immunology Research</i> , 2022, 10, 259-271.	3.4	10
61	Chiral induction in cyclopentyl-derived 1,3-meso-diester: enantioselective hydrolyses with electric eel acetylcholinesterase. <i>Tetrahedron: Asymmetry</i> , 1999, 10, 2139-2152.	1.8	9
62	Hyperfractionated abdominal reirradiation for gastrointestinal malignancies. <i>Radiation Oncology</i> , 2018, 13, 143.	2.7	9
63	Resolving the HIF paradox in pancreatic cancer. <i>Cancer Letters</i> , 2020, 489, 50-55.	7.2	9
64	Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration-based image guidance. <i>Radiation Oncology</i> , 2019, 14, 154.	2.7	8
65	A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 135-142.	0.8	8
66	The Therapeutic Potential of FLASH-RT for Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 1167.	3.7	8
67	Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 78-88.	0.8	8
68	Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. <i>Cancers</i> , 2020, 12, 2487.	3.7	7
69	Food and Drug Administration approvals in phase 3 Cancer clinical trials. <i>BMC Cancer</i> , 2021, 21, 695.	2.6	7
70	Radiation Sciences Education in Africa: An Assessment of Current Training Practices and Evaluation of a High-Yield Course in Radiation Biology and Radiation Physics. <i>JCO Global Oncology</i> , 2020, 6, 1631-1638.	1.8	7
71	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. <i>Oncologist</i> , 2022, 27, 40-47.	3.7	7
72	Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations. <i>Seminars in Radiation Oncology</i> , 2022, 32, 125-134.	2.2	7

#	ARTICLE	IF	CITATIONS
73	Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. <i>Cancer</i> , 2022, 128, 2529-2539.	4.1	7
74	Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. <i>JCO Oncology Practice</i> , 2020, 16, e1524-e1531.	2.9	6
75	Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy. <i>Brain, Behavior, and Immunity</i> , 2021, 98, 161-172.	4.1	6
76	Itâ€™s a SMAD/SMAD World. <i>Cell</i> , 2015, 161, 1245-1246.	28.9	5
77	IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 369-376.	1.2	5
78	Exclusion of Older Adults in COVID-19 Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2293-2294.	3.0	5
79	Professional Medical Writer Assistance in Oncology Clinical Trials. <i>Oncologist</i> , 2020, 25, e1812-e1815.	3.7	5
80	A Mail Audit Independent Peer Review System for Dosimetry Verification of a Small Animal Irradiator. <i>Radiation Research</i> , 2020, 193, 341.	1.5	5
81	Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 974-984.	0.8	5
82	Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. <i>Advances in Radiation Oncology</i> , 2018, 3, 595-600.	1.2	4
83	CEA as a blood-based biomarker in anal cancer. <i>Oncotarget</i> , 2021, 12, 1037-1045.	1.8	4
84	Impact factor and citation metrics in phase III cancer trials. <i>Oncotarget</i> , 2021, 12, 1780-1786.	1.8	4
85	Performance status restriction in phase III cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2059-2059.	1.6	4
86	Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2412-2422.	1.4	4
87	HIF2 Regulates Intestinal Wnt5a Expression. <i>Frontiers in Oncology</i> , 2021, 11, 769385.	2.8	4
88	Neutralizing interleukin-6 in tumor-bearing mice does not abrogate behavioral fatigue induced by Lewis lung carcinoma. <i>Behavioural Brain Research</i> , 2022, 417, 113607.	2.2	3
89	Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1270.	2.5	3
90	Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. <i>BMC Cancer</i> , 2022, 22, 174.	2.6	3

#	ARTICLE	IF	CITATIONS
91	Bi-directional regulation of brown fat adipogenesis by the insulin receptor.. Journal of Biological Chemistry, 2016, 291, 27434.	3.4	2
92	Divergent Regulation of Hepatic Glucose and Lipid Metabolism by Phosphoinositide 3-Kinase via Akt and PKC β /I β . Cell Metabolism, 2016, 23, 386.	16.2	2
93	EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal. Endoscopic Ultrasound, 2021, .	1.5	2
94	Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2021, 39, 3112-3112.	1.6	2
95	Insulin/IGF-1 Signaling Nodes and their Role in Carcinogenesis. Energy Balance and Cancer, 2011, , 53-76.	0.2	2
96	Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. BMJ Supportive and Palliative Care, 2022, 12, 42-45.	1.6	2
97	Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Clinical and Translational Radiation Oncology, 2022, 35, 9-16.	1.7	2
98	Initial Experience with Electronic Brachytherapy for Skin Cancer: Clinical and Dosimetric Characteristics. Brachytherapy, 2014, 13, S107.	0.5	1
99	Patient Setup Management for Pancreatic SBRT: Daily CT Based Assessment of Setup Accuracy using Vertebral Bone, Fiducial Markers, Biliary Stent, and Soft-Tissue Targeting. International Journal of Radiation Oncology Biology Physics, 2019, 105, E770.	0.8	1
100	Applying to Radiation Oncology Amid a Pandemic. Advances in Radiation Oncology, 2020, 5, 777-779.	1.2	1
101	Sponsor-involved statistical analyses in Phase III cancer clinical trials. International Journal of Cancer, 2020, 147, 3579-3581.	5.1	1
102	Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. Clinical Colorectal Cancer, 2020, 19, 116-122.	2.3	1
103	ADAM10 Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer. Cancer Research, 2021, 81, 3158-3159.	0.9	1
104	Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer. Metabolites, 2021, 11, 627.	2.9	1
105	Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, TPS4164-TPS4164.	1.6	1
106	The effect of IMRT on acute toxicity in patients with gastric cancer treated with preoperative chemoradiation.. Journal of Clinical Oncology, 2019, 37, 153-153.	1.6	1
107	Long-Term Patient-Reported Quality of Life and Functional Outcomes After Chemoradiation Using Intensity Modulated Radiotherapy for Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 111, S37-S38.	0.8	1
108	Patient-reported gastrointestinal outcomes in patients with anal cancer.. Journal of Clinical Oncology, 2020, 38, 4055-4055.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer.. Journal of Clinical Oncology, 2020, 38, TPS4670-TPS4670.	1.6	1
110	Pancreatic cancer intratumoral microbiome and characteristics within paired patient samples.. Journal of Clinical Oncology, 2020, 38, 744-744.	1.6	1
111	Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence. Clinical Colorectal Cancer, 2022, 21, 204-211.	2.3	1
112	Locally Advanced/Unresectable Pancreatic Cancer. Practical Guides in Radiation Oncology, 2018, , 231-256.	0.1	0
113	Gastrointestinal-activated Amifostine Ameliorates Morbid Toxicity from Stereotactic Radiation in a Murine Model. International Journal of Radiation Oncology Biology Physics, 2018, 102, S76.	0.8	0
114	Can IMRT Reduce Lymphopenia in Patients Treated with Preoperative Chemoradiation for Gastric Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 103, E11.	0.8	0
115	Assessing for Enhanced Radiosensitivity in Hypoxic Tumors by Blocking Oxidative Phosphorylation Using IACS-010759. International Journal of Radiation Oncology Biology Physics, 2019, 103, E22.	0.8	0
116	Does Fiducial Marker Placement Prior to SBRT Increase the Risk of Metastatic Disease in Patients with Unresectable Pancreatic Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 103, E31.	0.8	0
117	Data Analytics Platform for Outcome Comparison of Patients Treated for Primary Pancreatic Cancer Using SBRT vs Conventional RT. International Journal of Radiation Oncology Biology Physics, 2019, 103, E51.	0.8	0
118	923â€ŒEndoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients With Pancreatic Adenocarcinoma. American Journal of Gastroenterology, 2019, 114, S539-S540.	0.4	0
119	Phase III Radiation Oncology Clinical Trials: A Snapshot of the Last Two Decades. International Journal of Radiation Oncology Biology Physics, 2020, 108, e788-e789.	0.8	0
120	Outcomes with Proton and Photon Radiotherapy for Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2020, 108, E35-E36.	0.8	0
121	Clinical Associations of Treatment Failure After Radiation Therapy for Colorectal Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2020, 108, E53-E54.	0.8	0
122	How to Improve Enrollment Onto GI Radiation Oncology Clinical Trials: Lessons Learned From a Brachytherapy Trial for Newly Diagnosed Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, E55-E56.	0.8	0
123	Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clinical and Translational Radiation Oncology, 2021, 27, 147-151.	1.7	0
124	Development of an Objective Scoring System for Endoscopic Assessment of Radiation-Induced Upper Gastrointestinal Toxicity. Cancers, 2021, 13, 2136.	3.7	0
125	Clinical outcomes following definitive treatment of young-onset, locally advanced rectal cancer: A single institution experience.. Journal of Clinical Oncology, 2021, 39, e15601-e15601.	1.6	0
126	Lack of pre-planned financial outcomes evaluation in phase 3 cancer trials.. Journal of Clinical Oncology, 2021, 39, e18826-e18826.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Association of the anorectal microbiome and patient-reported gastrointestinal outcomes in patients with anal cancer.. Journal of Clinical Oncology, 2021, 39, e15504-e15504.	1.6	0
128	Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2021, , .	2.3	0
129	Outcomes and patterns of failures after hypofractionated radiation therapy for intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15609-e15609.	1.6	0
130	Abstract 3746: Fasting in mice enables abdominal radiation dose escalation in the setting of pancreatic cancer by mitigating small intestinal toxicity. , 2019, , .		0
131	Abstract 1402: Single cell transcriptomic profiling of ex vivo tumoroid models reveal therapeutic vulnerabilities of pancreatic ductal adenocarcinoma. , 2019, , .		0
132	Enhanced microbial diversity and chemoradiation response in HPV+ anal cancer.. Journal of Clinical Oncology, 2020, 38, 4-4.	1.6	0
133	The landscape of gastrointestinal oncologic phase III clinical trials in the last two decades.. Journal of Clinical Oncology, 2020, 38, e14087-e14087.	1.6	0
134	Professional medical writing assistance in oncology clinical trials.. Journal of Clinical Oncology, 2020, 38, e14088-e14088.	1.6	0
135	Abstract 555: Mitochondrial fusion exerts KRAS-dependent therapeutic synergy with gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer. , 2020, , .		0
136	A pilot course of intensive training in radiation biology and physics for oncologists in sub-Saharan Africa.. Journal of Global Oncology, 2019, 5, 24-24.	0.5	0
137	Abstract 3745: Mechanisms of HIF2-mediated small intestine radioprotection. , 2019, , .		0